Zepbound 2.5 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 2.5 mg/.5mL

Zepbound contains tirzepatide and acts on incretin pathways used in metabolic disease management.[2]

• Chronic weight management in adults with obesity: supports treatment alongside reduced-calorie diet and increased physical activity in eligible patients.[2]
• Chronic weight management in adults who are overweight and have at least one weight-related comorbidity: helps lower body weight in patients whose excess weight is associated with conditions such as hypertension, dyslipidaemia or type 2 diabetes risk.[2]

• Tirzepatide is a dual incretin receptor agonist that activates both GIP and GLP-1 receptors. This action increases glucose-dependent insulin secretion, decreases glucagon secretion, and slows gastric emptying, while also influencing appetite regulation and energy intake. These combined effects underpin its use in chronic weight management and metabolic risk reduction.[2]

Like all prescription injections, Zepbound may cause adverse reactions. Reported effects range from common gastrointestinal symptoms to rarer but more serious safety concerns.[2]

Common Side Effects

• Nausea: one of the most frequently reported adverse effects.[2]
• Diarrhea: can occur during treatment, especially early in therapy.[2]
• Vomiting: may be associated with reduced food intake and dehydration risk.[2]
• Constipation: has been reported among common gastrointestinal effects.[2]

Serious or Rare Side Effects

• Pancreatitis: severe persistent abdominal pain requires urgent assessment.[2]
• Gallbladder problems: including cholelithiasis or cholecystitis.[2]
• Hypoglycaemia: risk is higher when used with insulin or insulin secretagogues.[2]
• Acute kidney injury: may occur in the setting of severe dehydration from vomiting or diarrhoea.[2]

Zepbound is a prescription injection with important warnings and handling requirements. Clinical monitoring and label-directed use are essential.[2]

• Screen for contraindications: do not use in patients with a personal or family history of medullary thyroid carcinoma or in those with MEN 2.[2]
• Review pancreatitis history: discontinue and evaluate if symptoms suggest acute pancreatitis.[2]
• Assess gallbladder risk: report right upper abdominal pain, fever or jaundice promptly.[2]
• Use caution with hypoglycaemia-prone therapy: insulin or sulfonylureas may increase low-blood-sugar risk.[2]
• Monitor hydration: persistent vomiting or diarrhoea can worsen renal function.[2]
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.[2]

Tirzepatide can interact clinically with other glucose-lowering medicines and with drugs whose absorption may be affected by delayed gastric emptying.[2]

Major Interactions (Avoid)

• Hypoglycaemic combination risk: avoid unplanned use with insulin or sulfonylureas without prescriber review because low blood sugar may occur.[2]
• Severe intolerance risk: avoid duplicate incretin-based therapy unless specifically directed, as additive GI effects are possible.[2]

Moderate Interactions (Monitor Closely)

• Oral medicines with narrow timing needs: delayed gastric emptying may affect absorption of some drugs.[2]
• Antidiabetic therapy adjustments: blood glucose may change when tirzepatide is added to an existing regimen.[2]
• Dehydration-promoting medicines: diuretics or other agents that worsen fluid loss may increase renal risk if vomiting or diarrhoea occur.[2]